Capricor Therapeutics, Inc. (CAPR) EPS Estimated At $-0.11; Stepan Co (SCL)’s Sentiment Is 1.35

April 24, 2018 - By Dolores Ford

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Logo

Analysts expect Capricor Therapeutics, Inc. (NASDAQ:CAPR) to report $-0.11 EPS on May, 21.They anticipate $0.06 EPS change or 35.29% from last quarter’s $-0.17 EPS. After having $-0.11 EPS previously, Capricor Therapeutics, Inc.’s analysts see 0.00% EPS growth. The stock decreased 1.44% or $0.0196 during the last trading session, reaching $1.3404. About 124,143 shares traded. Capricor Therapeutics, Inc. (NASDAQ:CAPR) has declined 60.12% since April 24, 2017 and is downtrending. It has underperformed by 71.67% the S&P500.

Stepan Co (SCL) investors sentiment increased to 1.35 in Q4 2017. It’s up 0.32, from 1.03 in 2017Q3. The ratio increased, as 92 hedge funds started new and increased positions, while 68 decreased and sold their stock positions in Stepan Co. The hedge funds in our database now possess: 13.90 million shares, down from 13.94 million shares in 2017Q3. Also, the number of hedge funds holding Stepan Co in top ten positions was flat from 1 to 1 for the same number . Sold All: 15 Reduced: 53 Increased: 64 New Position: 28.

The stock decreased 16.56% or $14.78 during the last trading session, reaching $74.47. About 213,297 shares traded or 147.97% up from the average. Stepan Company (SCL) has risen 5.71% since April 24, 2017 and is uptrending. It has underperformed by 5.84% the S&P500.

Since January 1, 0001, it had 0 buys, and 9 selling transactions for $4.74 million activity.

Hillcrest Asset Management Llc holds 2.07% of its portfolio in Stepan Company for 137,078 shares. Grace & White Inc Ny owns 126,936 shares or 2.01% of their US portfolio. Moreover, Walthausen & Co. Llc has 0.97% invested in the company for 129,565 shares. The Connecticut-based Matarin Capital Management Llc has invested 0.83% in the stock. Capital Management Associates Ny, a New York-based fund reported 4,500 shares.

Stepan Company, together with its subsidiaries, produces and sells specialty and intermediate chemicals to other manufacturers for use in various end products worldwide. The company has market cap of $1.68 billion. It operates in three divisions: Surfactants, Polymers, and Specialty Products. It has a 19 P/E ratio. The Surfactants segment offers surfactants that are used as principal ingredients in consumer and industrial cleaning products, such as detergents for washing clothes, dishes, carpets, floors, and walls, as well as shampoos and body washes; and other applications, including fabric softeners, germicidal quaternary compounds, and lubricating ingredients, as well as emulsifiers for spreading agricultural products and industrial applications, such as latex systems, plastics, and composites.

Investors sentiment increased to 4.33 in Q4 2017. Its up 2.53, from 1.8 in 2017Q3. It increased, as 3 investors sold Capricor Therapeutics, Inc. shares while 0 reduced holdings. 7 funds opened positions while 6 raised stakes. 4.44 million shares or 503.95% more from 735,965 shares in 2017Q3 were reported. Citadel Advsr Ltd Liability Com has 10,009 shares. Geode Capital Mngmt Limited Co has 76,996 shares for 0% of their portfolio. Fincl Bank Of America De reported 6,500 shares or 0% of all its holdings. Fincl Bank Of New York Mellon holds 0% of its portfolio in Capricor Therapeutics, Inc. (NASDAQ:CAPR) for 27,442 shares. Deutsche Bancorporation Ag reported 0% of its portfolio in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Brown Advisory has invested 0.01% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Northern Trust Corp holds 38,660 shares or 0% of its portfolio. Perceptive Ltd Liability Company has 0% invested in Capricor Therapeutics, Inc. (NASDAQ:CAPR). 35,300 were reported by Wells Fargo And Com Mn. Blackrock reported 0% stake. Cordasco Finance Networks has 3,100 shares. Apriem Advsrs owns 50,000 shares. Royal Bancorporation Of Canada accumulated 232 shares or 0% of the stock. Acadian Asset Management Ltd Limited Liability Company stated it has 47,489 shares. Vanguard Group Inc Inc has 713,756 shares.

Among 2 analysts covering Capricor Therapeutics (NASDAQ:CAPR), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Capricor Therapeutics had 6 analyst reports since June 15, 2016 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Monday, July 10 report. As per Friday, September 15, the company rating was maintained by H.C. Wainwright. The stock has “Buy” rating by H.C. Wainwright on Thursday, March 29. The firm earned “Buy” rating on Wednesday, June 15 by Roth Capital. The firm has “Buy” rating by H.C. Wainwright given on Wednesday, July 6. On Friday, January 26 the stock rating was maintained by H.C. Wainwright with “Buy”.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of novel therapeutics primarily for the treatment of cardiovascular diseases. The company has market cap of $37.15 million. The company's development stage drug candidates for cardiovascular diseases include CAP-1002 that is in Phase II clinical trials; and CAP-2003, which is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. It has a 14.89 P/E ratio.

Stepan Company (NYSE:SCL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Dolores Ford

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: